A phase 1, open-label, dose escalation study on the safety and tolerability of ANK-101 in advanced solid tumors.

ANK-101 - Ankyra Therap

Jong Chul Park; Marcus O. Butler; Brendan D. Curti; Leisha A. Emens; Danielle M. Pastor; Joseph Elassal; Howard L. Kaufman; John M. Kirkwood

Apr 25, 2024